Vertex Pharmaceuticals (VRTX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $134.06B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Reshma Kewalramani |
| IPO Date | 1991-07-24 | CAGR | 27.73% |
| Employees | 6,400 | Website | www.vrtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.86% | Total Yield | 0.86% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $132.80B | P/E | 27.76 | Forward P/E | 24.21 | PEG | 3.75 |
| P/S | 18.38 | P/B | 11.48 | P/CF | 54.1 | P/FCF | 61.18 |
| Sales | $12.62B | Sales 1Y | 10.56% | Sales 3Y | 32.82% | Sales 5Y | 88.88% |
| EPS | $19.03 | EPS 1Y | 22.8% | EPS 3Y | 32.66% | EPS 5Y | 126.65% |
| Sales QoQ | 11.62% | EPS QoQ | 7.21% | Sales QoQ Avg | 3.21% | EPS QoQ Avg | 2.41% |
| Gross Margin | 86.04% | Operating Margin | 38.59% | Profit Margin | 34.89% | ROCE | 20.74% |
| ROA | 16% | ROE | 23% | Altman Z Score | 13.48 | Piotroski Score | 5 |
| Current Ratio | 3.19 | Quick Ratio | 2.74 | Cash Ratio | 1.99 | Op. CF Ratio | 0.29 |
| Debt/Equity | 0.1 | Debt/Assets | 0.07 | Lt Debt/Equity | 0.1 | Lt Debt/Cap. | — |
| Intrst Cov. | 738.18 | Inventory Turnover | 1 | Asset Turnover | 0.46 | Receivables Turnover | 5.91 |
| Enterprise Value | $132.80B | P/E Ratio | 27.76 |
| Forward P/E | 24.21 | PEG Ratio | 3.75 |
| P/S Ratio | 18.38 | P/B Ratio | 11.48 |
| P/CF Ratio | 54.1 | P/FCF Ratio | 61.18 |
| EPS | $19.03 | EPS Growth 1Y | 22.8% |
| EPS Growth 3Y | 32.66% | EPS Growth 5Y | 126.65% |
| Revenue Growth 1Y | 10.56% | Gross Margin | 0.86% |
| Operating Margin | 0.39% | Profit Margin | 0.35% |
| ROE | 0.23% | ROA | 0.16% |
| ROCE | 0.21% | Current Ratio | 3.19 |
| Quick Ratio | 2.74 | Cash Ratio | 1.99 |
| Debt/Equity | 0.1 | Interest Coverage | 738.18 |
| Altman Z Score | 13.48 | Piotroski Score | 5 |
Vertex Pharmaceuticals (VRTX) valuation & financials
Vertex Pharmaceuticals (VRTX) has a market capitalization of $134.06B and trades at a price-to-earnings ratio of 27.8. It operates in the Healthcare sector (Biotechnology).
Vertex Pharmaceuticals's revenue grew +10.6% over the last year.
Vertex Pharmaceuticals's next earnings report is scheduled for November 2, 2026 after market close; analysts estimate EPS of $4.91. Check the earnings calendar to see all companies reporting this week.
Vertex Pharmaceuticals (VRTX) — frequently asked questions
When does Vertex Pharmaceuticals (VRTX) report earnings next?
Vertex Pharmaceuticals is expected to report earnings on November 2, 2026 after market close. Analysts estimate EPS of $4.91.
What is Vertex Pharmaceuticals's market cap?
Vertex Pharmaceuticals (VRTX) has a market capitalization of $134.06B.
What is VRTX's P/E ratio?
Vertex Pharmaceuticals trades at a price-to-earnings ratio of 27.8, with trailing twelve-month EPS of $19.03.
How fast is Vertex Pharmaceuticals growing?
Vertex Pharmaceuticals's revenue grew +10.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)